10-Q: enGene Holdings Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Sentiment:

Quarterly Report 11 March 2024 5:12 PM

enGene Holdings Inc. reported a net loss of $10.7 million for the first quarter of 2024, while highlighting progress in its clinical development programs and a recent $200 million private placement.

Capital raiseThe company completed a private placement of 20,000,000 common shares at a price of $10.00 per share, resulting in gross proceeds of $200 million.The net proceeds from the private placement were approximately $187.5 million after deducting offering expenses.

Worse than expectedThe company's net loss increased compared to the same period last year, indicating a worsening financial performance.

Summary

enGene Holdings Inc. reported a net loss of $10.7 million for the three months ended January 31, 2024, compared to a net loss of $7.4 million for the same period in 2023.
Research and development expenses increased to $5.6 million, up from $3.7 million in the prior year, driven by increased clinical trial activity and personnel costs.
General and administrative expenses also rose significantly to $5.1 million, compared to $1.0 million in the prior year, primarily due to costs associated with operating as a public company and the reverse recapitalization.
The company's cash and cash equivalents stood at $85.6 million as of January 31, 2024.
A private placement of 20 million common shares at $10.00 per share, completed in February 2024, raised gross proceeds of $200 million.
The company believes its current cash position, along with the proceeds from the private placement, will fund operations into 2027.
The company is focused on advancing its lead product candidate, EG-70, through its pivotal-stage LEGEND study and plans to file a Biologics License Application in the first quarter of 2026.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has secured significant funding and is progressing its clinical programs, it also reports increased losses and identifies material weaknesses in internal controls. The CEO transition also adds uncertainty. The sentiment is therefore neutral to slightly positive.

Positives

The company successfully completed a $200 million private placement, significantly strengthening its financial position.
The company believes its current cash and the proceeds from the private placement will fund operations into 2027.
The company is making progress in its clinical development programs, particularly with EG-70.
The company has a clear timeline for filing a Biologics License Application for EG-70 in the first quarter of 2026.

Negatives

The company reported a net loss of $10.7 million for the first quarter of 2024, an increase from the $7.4 million loss in the same period of 2023.
Operating expenses, particularly research and development and general and administrative costs, have increased significantly.
The company has a history of operating losses and negative cash flows, and expects this to continue for the foreseeable future.
The company's disclosure controls and procedures were deemed ineffective due to identified material weaknesses in internal control over financial reporting.

Risks

The company has a history of operating losses and negative cash flows, and expects this to continue for the foreseeable future.
The company's ability to continue as a going concern depends on its ability to successfully develop and commercialize its products and raise additional capital.
The company's disclosure controls and procedures were deemed ineffective due to identified material weaknesses in internal control over financial reporting.
The company is subject to risks associated with clinical trials, regulatory approvals, and market acceptance of its product candidates.
The company is dependent on third-party manufacturers and contract research organizations.
The company is exposed to interest rate risk due to its variable-rate term loan.
The company is exposed to foreign currency exchange risk due to its operations in Canada and the United States.
The company is undergoing a CEO transition, which could impact operations and strategy.

Future Outlook

The company expects its current cash and cash equivalents, along with the proceeds from the recent private placement, to fund operations into 2027. The company is focused on advancing its EG-70 clinical program and plans to file a Biologics License Application in the first quarter of 2026.

Management Comments

Management believes that the existing cash and cash equivalents, together with the net proceeds from the Private Placement Financing, will be sufficient to fund operating expenses, debt obligations, and capital expenditure requirements into 2027.
Management is focused on advancing the ongoing pivotal-stage LEGEND study of EG-70 in BCG-unresponsive NMIBC to completion.

Industry Context

This announcement comes as the gene therapy sector continues to attract significant investment and attention. enGene's focus on non-viral gene therapies and its proprietary DDX platform positions it to potentially address a broader range of diseases than traditional gene therapy approaches. The company's progress with EG-70 in NMIBC is particularly relevant given the unmet need in this area.

Comparison to Industry Standards

The increase in R&D spending is typical for a clinical-stage biotech company advancing its lead candidate through pivotal trials. Companies like BioMarin Pharmaceutical and Sarepta Therapeutics, which are also in the gene therapy space, have similarly high R&D expenses during their clinical development phases.
The increase in G&A expenses is also expected for a company that has recently become public, as it needs to build out its infrastructure to comply with public company reporting requirements. This is similar to other companies that have recently completed a SPAC merger or IPO.
The $200 million private placement is a significant capital raise, which is comparable to other biotech companies that have recently raised capital to fund their clinical programs. For example, companies like Rocket Pharmaceuticals and Passage Bio have raised similar amounts in recent years.
The company's cash runway into 2027 is a positive sign, as it provides the company with sufficient time to execute its clinical development plans. This is comparable to other biotech companies that have recently raised capital and have a similar cash runway.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	Jason D. Hanson	TBD	TBD	Jason D. Hanson resigned due to personal family and health reasons.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Internal Control Weaknesses	The company identified material weaknesses in its internal control over financial reporting related to lack of formal policies, procedures, and controls, insufficient accounting personnel, lack of GAAP expertise, inadequate IT controls, and lack of segregation of duties.	January 31, 2024	The company's disclosure controls and procedures were deemed ineffective, and there is a risk of material misstatements in financial reporting.

Legal Proceedings

The company is not currently involved in any legal proceedings that are likely to have a significant negative effect on its business.

Related Party Transactions

A director, Mr. Gerry Brunk, is a managing director of Lumira Ventures, and certain entities affiliated with Lumira were party to the 2024 Subscription Agreements, purchasing an aggregate of 800,000 Common Shares for a total price of $8 million in the Company's 2024 PIPE Financing.

Stakeholder Impact

Shareholders: The company's financial performance and progress in clinical development will impact shareholder value. The recent private placement has diluted existing shareholders.
Employees: The CEO transition and the company's financial performance may impact employee morale and job security.
Customers: The company's progress in developing its product candidates will impact the availability of new treatment options for patients.
Suppliers: The company's financial stability and ability to pay its suppliers will be impacted by its financial performance.
Creditors: The company's ability to repay its debt obligations will be impacted by its financial performance.

Next Steps

The company will continue to advance the ongoing pivotal-stage LEGEND study of EG-70 in BCG-unresponsive NMIBC.
The company plans to file a Biologics License Application for EG-70 in the first quarter of 2026.
The company will continue to pursue potential pipeline expansion via additional EG-70 development opportunities and advance its preclinical program EG-i08 and other compounds.
The company will implement measures to remediate the identified material weaknesses in internal control over financial reporting.
The company will continue the search for a new Chief Executive Officer.

Key Dates

Date	Description
April 24, 2023	enGene Holdings Inc. was incorporated as 14963148 Canada Inc.
May 9, 2023	14963148 Canada Inc. changed its name to enGene Holdings Inc.
May 16, 2023	Date of the business combination agreement between enGene, FEAC and Old enGene.
October 31, 2023	The Reverse Recapitalization was completed, and the company became publicly traded.
November 1, 2023	enGene Holdings Inc. began trading on the Nasdaq Global Market under the symbols ENGN and ENGNW.
December 22, 2023	The company entered into an amended and restated loan and security agreement with Hercules Capital.
January 31, 2024	End of the reporting period for the first quarter financial results.
February 13, 2024	The company entered into subscription agreements for a private placement of 20 million common shares.
February 20, 2024	The private placement of 20 million common shares was completed.
March 5, 2024	The company's registration statement on Form S-1 was declared effective, ending the cashless warrant exercise period.
March 7, 2024	Date of outstanding share data provided in the document.
March 11, 2024	Date of the report and certifications.

Keywords

gene therapy, biotechnology, clinical trials, EG-70, NMIBC, private placement, financial results, research and development, operating expenses, internal controls

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.